Clinical trial · no report yet · Phase 3
ADAURA2
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
- NCT05120349 ↗
- Active not recruiting
- AstraZeneca
- 27 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 13 | |
| Podcasts | 10 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib; Placebo
- Arms
- Osimertinib · Experimental
- Placebo · Placebo comparator
- Enrollment
- 390
- Primary outcomes
- Disease-Free Survival (DFS) in high-risk stratum
- Sponsor
- AstraZeneca
- Start
- Feb 21, 2022
- Primary completion
- Aug 2, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05120349 · updated Jul 6, 2026
Publications
linked from the registry- Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18. PubMed 40311309